WU LESTER has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in Canada, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are BELITE BIO INC, LIVZON PHARMACEUTICAL GROUP IN and AMURA LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 2 | |
#2 | China | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | Republic of Korea | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Philippines | 1 | |
#7 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Yang Chuan-Ching | 10 |
#2 | Zhong Nanshan | 6 |
#3 | Tu Chi-Chiang | 5 |
#4 | Lin Mau-Yuan | 5 |
#5 | Hsiao Chia-Yen | 5 |
#6 | Lin Mao-Yuan | 5 |
#7 | Chen Kun-Hung | 5 |
#8 | Yang Chuan Ching | 2 |
#9 | Lin Mao Yuan | 1 |
#10 | Tu Chi Chiang | 1 |
Publication | Filing date | Title |
---|---|---|
KR20190099439A | Pharmaceutical Compositions of Benzenesulfonamide Derivatives for the Treatment of Adenoid Cystic Cancer | |
CN109475517A | For treating the novel benzsulfamide composition of malignant pleural effusion |